摘要
目的研究乌体林斯联合顺铂治疗恶性胸腔积液的临床疗效。方法将64例恶性胸水患者随机分为治疗组和对照组各32例,治疗组用乌体林斯加顺铂胸腔内注射,对照组单用顺铂胸腔内注射,观察治疗前后的近期疗效、活动状况、外周血免疫指标变化和不良反应。结果治疗组的近期疗效、活动状况改善程度均明显优于对照组(P<0.01);治疗组治疗后的CD3、CD4、CD4/CD8及自然杀伤细胞活性均高于治疗前(P<0.05),对照组免疫指标治疗前后无明显变化,治疗后两组免疫指标比较差异有统计学意义(P<0.05);治疗组不良反应仅为发热、胸痛,而对照组出现骨髓抑制、胃肠道反应和胸痛。结论乌体林斯联合顺铂胸腔注射治疗恶性胸水有较好的临床疗效。
Objective To study malignant the therapeutic efficacy of intrapleural injection of mycobacterium phlei F.U.36 with cisplatin in the treatment of pleural effusion. Methods Sixty-four patients of malignant pleural effusion were randomized into treatment group and control group;32 patients were treated with mycobacterium phlei F.U.36 and cisplatin intrapleural injection(treatment group),and 32 patients were treated with cisplatin intrapleural injection only(control group).The therapeutic efficacy, change of performance,immunological criteria and side effects were compared between the two groups. Results The therapeutic efficacy and performance improvement were singnificantly higher in treatment group than that of control group(P<(0.01)). CD3, CD4, CD4/CD8 and activity of natural killer cells showed significant marked elevation in treatment group as compared with that before treatment(P<(0.05)), but no improvement was observed in control group. The side effects of treatment group were only low fever and mild pleurodynia, while those of control group were myelosuppression, gastrointestinal reaction and pleurodynia. Conclusion Intrapleural injection of mycobacterium phlei F.U.36 with cisplatin has better efficacy in treating malignant pleural effusion.
出处
《临床荟萃》
CAS
北大核心
2005年第12期670-672,共3页
Clinical Focus
关键词
胸腔积液
乌体林斯
顺铂
pleural effusion
mycobacterium phlei F.U.36
cisplatin
